Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U01 - Clinical Trials Required)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to support hybrid effectiveness-implementation trials for heart, lung, blood, and sleep (HLBS) diseases in the inpatient setting. NHLBI is seeking applications that propose a trial testing an implementation strategy (or strategies) that was developed utilizing an implementation research framework and that aims to increase implementation of an evidence-based practice(s). This FOA intends to support applications that propose a multidisciplinary research team that includes expertise in inpatient clinical research, implementation research, and biostatistics. Any applicant proposing a trial that meets the requirements of this FOA is eligible to apply, regardless of participation in Preparing for Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U01) (RFA-HL-18-018).

Deadlines:

  • Letter of Intent Due Date(s): November 9, 2020

  • Application Due Date(s): December 9, 2020

RFA-HL-21-001 Expiration Date December 10, 2020

Agency Website

Amount Description

Application budgets are limited to $400,000 in direct costs in FY 2021, and $675,000 per year in FY 2022 through FY 2025. Applications budgets should reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Funding Type

Grant

Eligibility

Faculty

Category

Engineering and Physical Sciences
Environmental & Life Sciences
Interdisciplinary
Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

December 9, 2020